Volume 2.41 | Nov 4

Prostate Cell News 2.41, November 4, 2011
     In this issue: Publications | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
Antiangiogenic Thrombospondin-1 Triggers Cell Migration and Development of Advanced Prostate Tumors
Researchers reevaluated the role of the endogenous antiangiogenic Thrombospondin 1 in prostate carcinomas where angiogenesis is an active process. [Cancer Res] Abstract

PUBLICATIONS (Ranked by Impact Factor of the Journal)


Consumption of High ω-3 Fatty Acid Diet Suppressed Prostate Tumorigenesis in C3(1) Tag Mice
Researchers investigated whether changing from a diet that approximates ω-6 fat content of the Western diet to a high ω-3 fat diet at adulthood might reduce prostate cancer risk. [Carcinogenesis] Abstract

A Dormant State Modulated by Osmotic Pressure Controls Clonogenicity of Prostate Cancer Cells
In this work, researchers describe the rapid induction in vitro of a dormant state in prostate cancer cells by exposure to a slightly hypertonic growth medium. [J Biol Chem] Abstract

The miR-183-96-182 Cluster Is Overexpressed in Prostate Tissue and Regulates Zinc Homeostasis in Prostate Cells
Researchers observed regulation of zinc homeostasis by a microRNA (miR) cluster in prostate cells and HEK-293 cells, suggesting a universal mechanism that is not prostate specific. [J Biol Chem] Abstract

Testosterone Regulates Smooth Muscle Contractile Pathways in the Rat Prostate: Emphasis on Phosphodiesterase V (PDE5) Signaling
This study investigated the effect of testosterone (T) on smooth muscle contractile and regulatory signaling pathways including PDE5 expression and functional activity in prostate in male rats (sham-operated, surgically-castrated and castrated with T supplementation). [Am J Physiol Endocrinol Metab] Abstract

Notch Activation by Phenethyl Isothiocyanate Attenuates Its Inhibitory Effect on Prostate Cancer Cell Migration
This present study demonstrates, for the first time, that phenethyl isothiocyanate treatment activates Notch signaling in malignant as well as normal human prostate cells. [PLoS One] Abstract

PTEN Genomic Deletions that Characterize Aggressive Prostate Cancer Originate Close to Segmental Duplications
Data suggests that a strong selective growth advantage for loss of PTEN and upregulation of PI3K/AKT, combined with the close proximity of PTEN to a large unstable segment of repeated DNA comprising SD17 and SD18, can lead to recurrent microdeletions of the PTEN gene in prostate cancer. [Genes Chromosomes Cancer] Abstract

Development and Characterization of a Novel C-Terminal Inhibitor of Hsp90 in Androgen Dependent and Independent Prostate Cancer Cells
Researchers’ findings suggest C-terminal heat shock protein 90 (Hsp90) inhibitors have potential as therapeutic agents for the treatment of prostate cancer. [BMC Cancer] Abstract


Duration of Short-Course Androgen Suppression Therapy and the Risk of Death as a Result of Prostate Cancer
Researchers evaluated whether the duration of androgen suppression therapy had an impact on the risk of prostate cancer–specific mortality in men with unfavorable-risk prostate cancer within established Gleason score categories. [J Clin Oncol] Abstract

Randomized, Double-Blind, Placebo Controlled Trial of Polyphenon E in Prostate Cancer Patients Before Prostatectomy: Evaluation of Potential Chemopreventive Activities
The study aimed to determine the bioavailability of green tea polyphenols in prostate tissue and to measure its effects on systemic and tissue biomarkers of prostate cancer carcinogenesis. [Cancer Prev Res] Abstract

Type of Transrectal Ultrasonography Probe Influences Prostate Cancer Detection Rates on Repeat Prostate Biopsy
The objective of this study was to determine if the type of transrectal ultrasonography probe used during repeat prostate biopsy influences prostate cancer detection rates. [BJU Int] Abstract

Utility of PCA3 in Patients Undergoing Repeat Biopsy for Prostate Cancer
Researchers sought to define the utility of prostate cancer antigen 3 (PCA3) in combination with other clinical data in predicting the risk of prostate cancer on repeat biopsy. [Prostate Cancer Prostatic Dis] Abstract



Medivation and Astellas Announce Positive Survival Data from Interim Analysis of Phase III AFFIRM Trial of MDV3100 in Men with Advanced Prostate Cancer
Medivation, Inc. and Astellas Pharma Inc. announced that the Independent Data Monitoring Committee has informed the companies of positive results from a planned interim analysis of the Phase III AFFIRM trial of MDV3100 in men with advanced prostate cancer previously treated with chemotherapy. [Medivation, Inc.] Press Release

Adamis Prostate Cancer Drug APC-100 Receives Allowance for Patent in Canada
Adamis Pharmaceuticals Corporation, announced the technology which constitutes its compound APC-100 received a Notice of Allowance for its patent application in Canada. Broad claims to a patent entitled “Chroman-Derived Anti-Androgens for Treatment of Androgen-Mediated Disorders” have been allowed. [BusinessWire] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW 2012 Genitourinary Cancers Symposium – Novel Mechanisms and Therapies in Multidisciplinary Management
February 2-4, 2012 
San Francisco, United States

our events page to see a complete list of events in the prostate cell community.

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Scientist (iPSC) (STEMCELL Technologies)

Contract Assay Service Technologist (STEMCELL Technologies)

Research and Development Technologist, hPSC Media (STEMCELL Technologies) 

Lab Technologist – Pluripotent Stem Cells (STEMCELL Technologies)

Quality Control Technologist  Cell Separation (STEMCELL Technologies)

Scientist – Pluripotent Stem Cells (STEMCELL Technologies)

Research Associate – Development (Precision Therapeutics, Inc.) 

Postdoc – Prostate Cancer (Weill Cornell Medical College) 

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us